Dr Bhat on Choosing Between Pirtobrutinib and Liso-Cel for R/R CLL Management
Seema A. Bhat, MD, discusses disease features and patient characteristics that inform the choice between pirtobrutinib and liso-cel for CLL.
Related Articles
Pooled Analysis Shows POD24 Strongly Predicts Poor Survival in Newly Diagnosed MCL
Early progression or death within 24 months of first-line treatment was linked to inferior survival in mantle cell lymphoma.
Experts Spotlight Noteworthy GU Cancer Abstracts Ahead of the 2025 ASCO Annual Meeting
Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.
FDA Issues Refusal to File Letter for Nogapendekin Alfa Inbakicept sBLA in BCG-Unresponsive Papillary NMIBC
A meeting has been requested to address the FDA’s refusal to file an sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive papillary NMIBC.
Dr Heymach on the Efficacy of Zongertinib in Previously Treated HER2-Mutant NSCLC
John V. Heymach, MD, PhD, discusses the activity of zongertinib in patients with previously treated advanced HER2-mutant NSCLC.
FDA Grants Priority Review to Sevabertinib for HER2-Mutant NSCLC
The FDA granted priority review to sevabertinib for pretreated, advanced non–small cell lung cancer harboring HER2 mutations.
FOLFIRINOX Significantly Improves PFS Over Gemcitabine in Locally Advanced Pancreatic Carcinoma
NEOPAN data support the superiority of FOLFIRINOX over gemcitabine in locally advanced pancreatic carcinoma.
New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer
Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib.
Elotuzumab Plus PVd Has Antitumor Activity in Heavily Pretreated R/R Myeloma
Elotuzumab plus PVd elicited responses in patients with relapsed/refractory multiple myeloma after a median of 3 prior lines of therapy.
NCCN Guidelines Now Recommend Pemivibart for COVID-19 Prevention in B-Cell Lymphomas
Updated NCCN Guidelines recommend pemivibart in immunocompromised patients with B-cell lymphomas who are at higher risk of contracting COVID-19.
Health Canada, European Commission Approve Subcutaneous Nivolumab in the Same Solid Tumor Indications as IV Formulation
Nivolumab has been approved for subcutaneous use across several adult solid tumor indications that have an existing indication for intravenous use.